SmartTRAK will be attending the Society of Neurointerventional Surgery (SNIS) 23rd Annual Meeting at the Seattle Convention Center. To get you up to speed before the meeting, SmartTRAK has put together highlights of recent Neurovascular news. Below is just a small sampling of recent Neurovascular-related news and updates from around the world, compiled, reviewed and posted in real time every day by the expert analysts at SmartTRAK.
SmartTRAK will be attending SNIS 2026 from July 20-24. If you'd like to meet with us in person, please reach out to Anne Staylor, SmartTRAK’s Executive Editor and VP & GM, Neuro Therapies, at the show, just click the button below.
Market Updates:
-
Kaneka Shows Clear Intent in US Neurovascular Market
SmartTRAK notes that Kaneka NV is now training US physicians on a portfolio that combines its own i-ED coils and SurfRider 13 Microcatheter with products from two distribution agreements, WaveSelect and Toro 88, signaling a more intentional move into neurovascular. LinkedIn -
US Mechanical Thrombectomy Remains Underpenetrated
The US MT Market remains significantly underpenetrated and with fewer DMVO procedures, market penetration is slowing. In 2025, only ~30% of eligible AIS patients received MT therapy, increasing to 35% of eligible AIS pts receiving MT therapy by 2030E. SmartTRAK US MT Market Overview -
US Mechanical Thrombectomy Procedural Mix
SmartTRAK estimates the US MT procedural mix in 2025 was 65% Aspiration, 3% Stent Retriever (SR) only and 32% Combined technique. SmartTRAK US MT Market Overview -
US Mechanical Thrombectomy Device Use in 2025
Across all MT techniques (ADAPT, Combined, SR only and Bailout), the total no. of Aspiration devices used in 2025 was down -2.0% YoY, and the total no. of SR devices used was down -22% YoY. SmartTRAK US MT Market Overview -
US Mechanical Thrombectomy - RCTs Will Help Drive Growth
Although MT DMVO procedures have slowed and the market is focused on “precision thrombectomy,” RCTs demonstrating the effectiveness of MT in other patient populations (low ASPECTS, lg core strokes, late time window) will help drive growth in the next 5 years. -
US Mechanical Thrombectomy - 2nd-Gen RCTs and DMVO Rebound
The 2nd-gen studies underway to determine which pt subgroups and brain territories are most likely to benefit from DMVO MT procedures may provide the evidence needed to support a rebound in DMVO procedures over the next 5 years.
Clinical/Regulatory:
-
Penumbra
Penumbra announced that THUNDERBOLT received FDA clearance as the first computer‑assisted vacuum thrombectomy (CAVT) device for acute ischemic stroke, offering modulated aspiration to improve speed and completeness of clot removal and potentially transform stroke treatment. -
Toro Neurovascular
Toro Neurovascular announced that its Toro 88 Superbore Catheter has received FDA 510(k) clearance and the first clinical cases have been successfully completed. Kaneka Medical is leading the US launch of Toro 88. -
Serenity Shepard Stent Receives BDD for Pulsatile Tinnitus
Serenity Medical announced it received FDA Breakthrough Device Designation for its Serenity Shepard Stent System for the treatmen of severe pulsatile tinnitus. This follows the March 2026 HDE approval of Serenity’s River Stent for the treatment of refractory idiopathic intracranial hypertension. -
Sentante Secures CE Mark for Endovascular Robot
Sentante announced it has received CE Mark for its endovascular robot. The company will now begin its initial rollout, clinical training and commercial expansion. The robot has received FDA Breakthrough Device Designation and is in the Total Product Life Cycle Advisory Program. -
Balt USA
Balt USA received FDA 510(k) clearance for its Next Generation 088 Catheter on 4/16/26 for use in neuro, peripheral and coronary vasculatures. The guidewire will be packaged with a dilator, introducer sheath, 9F rotating hemostasis valve and 8F hemostasis valve adaptor.
Patents:
- Route 92
Route 92 Medical was issued US Patent "Catheter Systems For Applying Effective Suction In Remote Vessels And Thrombectomy Procedures Facilitated By Catheter Systems" describing a suction catheter with extendable nozzle that deploys and forms a sealed aspiration lumen. 12521523 -
Perfuze
Perfuze's US Patent Application "High Flexibility, Kink Resistant Catheter Shaft" was published describing a flexible, kink-resistant catheter with a corrugated distal shaft and helical reinforcement that enhances navigation through tortuous vessels. 20260151593 -
JNJ MedTech
Neuravi's US Patent Application "Clot Retrieval System For Removing Occlusive Clot From A Blood Vessel" was published describing an MT device with a flared distal barrel section and asymmetrical strut design to create varied radial force to improve clot engagement. 20260144558 -
Medtronic
Covidien was granted US Patent "Aspiration Systems And Methods And Expanding-mouth Catheters" describing an aspiration catheter with a radially expandable distal mouth that engages clot and cyclically expands/contracts at a controlled frequency to enhance clot capture. 12648783 -
Terumo Neuro
MicroVention was issued US Patent "Reinforced Balloon Catheter" describing a neurovascular balloon catheter system with a gas-permeable purge port and de-airing channel that vents trapped gas while blocking liquid passage during balloon inflation. 12616820
Deals/Financing:
-
Penumbra
For Q126, PEN noted that the company remains focused on its pending acquisition by Boston Scientific Corporation, which is expected to close in 2026. PEN Q126 Earnings Release -
Medtronic
Medtronic completed its acquisition of Scientia Vascular, valued at $550MM with potential additional earn-out and milestone payments post-acquisition. Scientia’s access product lines complement the MDT neurovascular portfolio for a full procedural workflow. -
Route 92
Route 92 Medical announced $50MM in growth financing led by Novo Holdings joined by new investor Sectoral Asset Mgmt and returning investors. Proceeds will help accelerate global commercial expansion, advance clinical evidence and continue product innovation across the platform. -
Imperative Care
Imperative Care closed an oversubscribed $100MM financing round with both new and existing investors participating. Proceeds will support the commercialization of existing thrombectomy products, the development of the Telos robotic platform and clinical evidence generation. -
First Neurovascular Robotic Technology Acquisition of 2026
Stereotaxis will acquire Robocath, currently selling the R-One+ robotic system for interventional cardiology and developing a system for neurointervention. The transaction, expected to close in mid-2026, includes a $20MM upfront payment and $25MM contingent on milestones. -
CereVasc Closes $85MM Series C
CereVasc closed an $85MM Series C financing round with both Johnson & Johnson Innovation (JJDC) and Medtronic as participating investors. Funds will be used to advance clinical and regulatory pathways for its eShunt minimally invasive treatment for Normal Pressure Hydrocephalus.
Studies:
-
Monopoint – Route 92
A meta-analysis of 7 studies (490 LVO pts) found the 0.088-inch HiPoint Reperfusion System increased first-pass effect (+18%) and near-complete reperfusion (+23%) vs other techniques, with 3% sICH, 94% reperfusion and significant NIHSS improvement. Neurosurg Rev -
Penumbra
Penumbra announced that it has initiated the FORWARD Study to evaluate mechanical thrombectomy and CAVT with its RED catheters and THUNDERBOLT in distal M2 occlusions. The first of 250 patients worldwide was enrolled by Dr. Keith Woodward in Knoxville, TN. -
Combined SR + Aspiration Improves Recanalization, Not Outcomes
A pooled analysis of the ASTER, ASTER2 and VECTOR RCTs found first-line combined stent retriever + aspiration achieved higher successful reperfusion without rescue therapy than aspiration or SR alone, but did not improve 90-day functional outcomes, NIHSS or safety. Eur Stroke J -
Study Shows IVT Before MT Yields Higher Recanalization Rates
A target trial emulation (N=347) evaluating the safety of omitting thrombolysis in extended windows found direct MT is not non-inferior to IVT+MT beyond 4.5 hours or at wake-up. The study concluded IVT before MT yields significantly higher successful recanalization rates. EJN -
ZOOM - Imperative Care
Imperative Care is sponsoring a 750-patient study evaluating ADAPT 2.0 first-line aspiration thrombectomy with its Zoom System with Continuous Dual Aspiration (CDAT) for AIS pts. Estimated start is March 2026. clinicaltrials.gov
Want to learn more about SmartTRAK’s Neuro Therapies coverage, including up-to-date intelligence on neuro therapy industry trends, news, financial data and competitor developments, just click the button below.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK offers and how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.
